Company: LENZ
Filing Date: 2025-04-14
Form Type: 424B5
Source: 0001628280-25-017695
Chunk: 21

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-14
Form: 424B5
Chunk 21
---
 or superseded. This prospectus supplement incorporates by reference the documents listed below and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents furnished pursuant to Items 2.02 or 7.01 of any Current Report on Form 8-K and, except as may be noted in any such Form 8-K, exhibits filed on such form that are related to such information) after the date of the initial registration statement of which this prospectus forms a part and prior to the effectiveness of the registration statement, as well as subsequent to the effectiveness of the registration statement, until the offering of the securities under the registration statement of which this prospectus supplement forms a part is terminated or completed:

• our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 19, 2025 ;

• our Item 1.01 and 9.01 Current Report on Form 8-K filed with the SEC on April 4, 2025 ; and

• the description of our Common Stock contained in the Annual Report on Form 10-K filed on March 19, 2025 .

You may request a copy of these filings, at no cost, by writing or telephoning us at the following address and telephone number:

<div align='center'>LENZ Therapeutics, Inc.

201 Lomas Santa Fe Dr., Suite 300

Solana Beach, California 92075

Attn: Investor Relations

(858) 925-7000

S-17</div>

#### PROSPECTUS

#### LENZ Therapeutics, Inc.
<div align='center'>$500,000,000</div>

#### Common Stock

#### Preferred Stock

#### Debt Securities

#### Depositary Shares

#### Warrants

#### Subscription Rights

#### Purchase Contracts

#### Units
We may issue securities from time to time in one or more offerings, in amounts, at prices and on terms determined at the time of offering. This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide the specific terms of these securities in supplements to this prospectus, which will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this prospectus. You should read this prospectus and any applicable prospect